松弛素作为一种治疗慢性肾病的新治疗途径的新兴作用。
The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.
机构信息
Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi.
出版信息
Am J Physiol Regul Integr Comp Physiol. 2013 Sep 15;305(6):R559-65. doi: 10.1152/ajpregu.00528.2012. Epub 2013 Jul 24.
Abstract
Emerging evidence supports a potential therapeutic role of relaxin in fibrotic diseases, including chronic kidney disease. Relaxin is a pleiotropic hormone, best characterized for its role in the reproductive system; however, recent studies have demonstrated a role of relaxin in the cardiorenal system. Both relaxin and its receptor, RXFP1, are expressed in the kidney, and relaxin has been shown to play a role in renal vasodilation, in sodium excretion, and as an antifibrotic agent. Together, these findings suggest that the kidney is a target organ of relaxin. Therefore, the purpose of this review is to describe the functional and structural impacts of relaxin treatment on the kidney and to discuss evidence that relaxin prevents disease progression in several experimental models of kidney disease. In addition, this review will present potential mechanisms that are involved in the therapeutic actions of relaxin.
摘要
新出现的证据支持松弛素在纤维化疾病中的潜在治疗作用，包括慢性肾脏病。松弛素是一种多功能激素，其在生殖系统中的作用最为突出；然而，最近的研究表明松弛素在心脏肾脏系统中也发挥作用。松弛素及其受体 RXFP1 在肾脏中均有表达，松弛素在肾脏血管舒张、钠排泄以及抗纤维化作用中发挥作用。这些发现表明肾脏是松弛素的靶器官。因此，本综述的目的是描述松弛素治疗对肾脏的功能和结构的影响，并讨论松弛素在几种肾脏疾病的实验模型中预防疾病进展的证据。此外，本综述将介绍参与松弛素治疗作用的潜在机制。
相似文献
1
The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.
Am J Physiol Regul Integr Comp Physiol. 2013 Sep 15;305(6):R559-65. doi: 10.1152/ajpregu.00528.2012. Epub 2013 Jul 24.
2
Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Kidney Int. 2014 Jul;86(1):75-85. doi: 10.1038/ki.2013.518. Epub 2014 Jan 15.
3
Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions.
Biochem Pharmacol. 2022 Mar;197:114884. doi: 10.1016/j.bcp.2021.114884. Epub 2021 Dec 27.
4
The anti-fibrotic actions of relaxin are mediated through AT R-associated protein phosphatases via RXFP1-AT R functional crosstalk in human cardiac myofibroblasts.
FASEB J. 2020 Jun;34(6):8217-8233. doi: 10.1096/fj.201902506R. Epub 2020 Apr 16.
5
The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.
Mol Genet Genomic Med. 2020 Apr;8(4):e1194. doi: 10.1002/mgg3.1194. Epub 2020 Feb 26.
6
Relaxin in hepatic fibrosis: What is known and where to head?
Biochimie. 2021 Aug;187:144-151. doi: 10.1016/j.biochi.2021.06.001. Epub 2021 Jun 5.
7
Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
Cell Tissue Res. 2018 Dec;374(3):619-627. doi: 10.1007/s00441-018-2904-0. Epub 2018 Aug 4.
8
G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention.
Hum Reprod Update. 2016 Sep;22(5):647-64. doi: 10.1093/humupd/dmw021. Epub 2016 Jul 6.
9
New targets for renal interstitial fibrosis: relaxin family peptide receptor 1-angiotensin type 2 receptor heterodimers.
Kidney Int. 2014 Jul;86(1):9-10. doi: 10.1038/ki.2014.22.
10
Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2.
FASEB J. 2009 Apr;23(4):1219-29. doi: 10.1096/fj.08-120857. Epub 2008 Dec 10.
引用本文的文献
1
Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets.
J Clin Med. 2024 Mar 25;13(7):1881. doi: 10.3390/jcm13071881.
2
.
Mater Today Bio. 2023 Jun 27;21:100716. doi: 10.1016/j.mtbio.2023.100716. eCollection 2023 Aug.
3
The tendon unit: biochemical, biomechanical, hormonal influences.
J Orthop Surg Res. 2023 Apr 21;18(1):311. doi: 10.1186/s13018-023-03796-4.
4
Identification of a distal RXFP1 gene enhancer with differential activity in fibrotic lung fibroblasts involving AP-1.
PLoS One. 2021 Dec 31;16(12):e0254466. doi: 10.1371/journal.pone.0254466. eCollection 2021.
5
Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta.
Biomolecules. 2020 Jun 24;10(6):953. doi: 10.3390/biom10060953.
6
The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.
Mol Genet Genomic Med. 2020 Apr;8(4):e1194. doi: 10.1002/mgg3.1194. Epub 2020 Feb 26.
7
Relaxin inhibits patellar tendon healing in rats: a histological and biochemical evaluation.
BMC Musculoskelet Disord. 2019 Jul 27;20(1):349. doi: 10.1186/s12891-019-2729-3.
8
Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.
Am J Physiol Heart Circ Physiol. 2019 Aug 1;317(2):H234-H242. doi: 10.1152/ajpheart.00174.2019. Epub 2019 May 24.
9
Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies.
Front Physiol. 2018 Feb 16;9:105. doi: 10.3389/fphys.2018.00105. eCollection 2018.
10
Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia.
Am J Physiol Regul Integr Comp Physiol. 2016 Dec 1;311(6):R1158-R1163. doi: 10.1152/ajpregu.00192.2016. Epub 2016 Sep 14.
本文引用的文献
1
Relaxin family peptides and their receptors.
Physiol Rev. 2013 Jan;93(1):405-80. doi: 10.1152/physrev.00001.2012.
2
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
Lancet. 2013 Jan 5;381(9860):29-39. doi: 10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7.
3
Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.
PLoS One. 2012;7(8):e42714. doi: 10.1371/journal.pone.0042714. Epub 2012 Aug 22.
4
Relaxin improves TNF-α-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling.
Cardiovasc Res. 2012 Jul 1;95(1):97-107. doi: 10.1093/cvr/cvs149. Epub 2012 Apr 16.
5
Treatment of chronic kidney disease.
Kidney Int. 2012 Feb;81(4):351-62. doi: 10.1038/ki.2011.380. Epub 2011 Dec 14.
6
Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects.
Cell Tissue Res. 2012 Jan;347(1):141-54. doi: 10.1007/s00441-011-1275-6. Epub 2011 Nov 22.
7
Relaxin ameliorates salt-sensitive hypertension and renal fibrosis.
Nephrol Dial Transplant. 2012 Jun;27(6):2190-7. doi: 10.1093/ndt/gfr618. Epub 2011 Nov 15.
8
Relaxin and castration in male mice protect from, but testosterone exacerbates, age-related cardiac and renal fibrosis, whereas estrogens are an independent determinant of organ size.
Endocrinology. 2012 Jan;153(1):188-99. doi: 10.1210/en.2011-1311. Epub 2011 Oct 25.
9
Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.
Hypertension. 2011 Aug;58(2):197-204. doi: 10.1161/HYPERTENSIONAHA.110.164392. Epub 2011 Jun 13.
10
Maternal vasodilation in pregnancy: the emerging role of relaxin.
Am J Physiol Regul Integr Comp Physiol. 2011 Aug;301(2):R267-75. doi: 10.1152/ajpregu.00156.2011. Epub 2011 May 25.
Zotero 插件